We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+14.43%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$166M
AUM Growth
-$10.9M
(-6.1%)
Cap. Flow
+$57M
Cap. Flow
% of AUM
34.24%
Top 10 Holdings %
Top 10 Hldgs %
65.79%
Holding
63
New
18
Increased
12
Reduced
1
Closed
32
Avg Time Held Equity + Options
1.1
quarters
Top 10 Avg Time Held Equity + Options
0.3
quarters
Top 20 Avg Time Held Equity + Options
0.6
quarters
Avg Time Held Equity only
1.3
quarters
Top 10 Avg Time Held Equity only
0.6
quarters
Top 20 Avg Time Held Equity only
1.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gyre Therapeutics
GYRE
|
+$23.6M |
| 2 |
Sanofi
SNY
|
+$17M |
| 3 |
Biogen
BIIB
|
+$9.9M |
| 4 |
Merck
MRK
|
+$6.5M |
| 5 |
Kura Oncology
KURA
|
+$5.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$11.6M |
| 2 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$7.06M |
| 3 |
AET
Aetna Inc
AET
|
+$4.75M |
| 4 |
Emergent Biosolutions
EBS
|
+$4.25M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$3.43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.02% |
| 2 | Miscellaneous | 3.77% |
| 3 | Financials | 3.21% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Gyre Therapeutics
GYRE
$709M
| $29.7M | 17.83% |
153,332
+126,361
| +469% | +$23.6M |
2017 Q2
3 quarters
|
|
|
2
Sanofi
SNY
$95.5B
| $16.4M | 9.84% |
+408,621
| New | +$17M |
2018 Q1
0 quarters
|
|
|
3
Kura Oncology
KURA
$857M
| $12.3M | 7.41% |
657,411
+265,384
| +68% | +$5.17M |
2017 Q3
2 quarters
|
|
4
Elevance Health
ELV
$92.4B
| $11.5M | 6.92% |
52,387
+7,941
| +18% | +$1.87M |
2017 Q2
3 quarters
|
|
|
5
Biogen
BIIB
$33.8B
| $8.73M | 5.25% |
+31,900
| New | +$9.9M |
2018 Q1
0 quarters
|
|
6
UnitedHealth
UNH
$350B
| $6.51M | 3.91% |
30,400
+18,970
| +166% | +$4.33M |
2016 Q3
6 quarters
|
|
7
Eli Lilly
LLY
$1.08T
| $6.37M | 3.83% |
82,363
+28,463
| +53% | +$2.29M |
2017 Q4
1 quarter
|
|
|
8
Merck
MRK
$363B
| $6.26M | 3.76% |
+120,369
| New | +$6.5M |
2018 Q1
0 quarters
|
|
9
Boston Scientific
BSX
$61.8B
| $6.16M | 3.7% |
225,463
+75,711
| +51% | +$2.06M |
2017 Q4
1 quarter
|
|
10
Viking Therapeutics
VKTX
$3.3B
| $5.58M | 3.35% |
1,276,845
+26,595
| +2% | +$147K |
2017 Q4
1 quarter
|
|
|
WCG
11
DELISTED
Wellcare Health Plans, Inc.
WCG
| $5.55M | 3.33% |
28,653
+5,453
| +24% | +$1.09M |
2017 Q4
1 quarter
|
|
|
AET
12
DELISTED
Aetna Inc
AET
| $5.35M | 3.21% |
31,635
-26,454
| -46% | -$4.75M |
2016 Q4
5 quarters
|
|
13
HCA Healthcare
HCA
$101B
| $5.08M | 3.05% |
+52,330
| New | +$5.08M |
2018 Q1
0 quarters
|
|
14
Icon
ICLR
$13B
| $4.28M | 2.57% |
36,200
+12,596
| +53% | +$1.44M |
2017 Q3
2 quarters
|
|
15
Accendra Health
ACH
$23M
| $4.25M | 2.56% |
+273,640
| New | +$4.88M |
2018 Q1
0 quarters
|
|
16
DELISTED
TruBridge
TBRG
| $3.33M | 2% |
113,860
+89,317
| +364% | +$2.67M |
2017 Q4
1 quarter
|
|
|
CFMS
17
DELISTED
Conformis, Inc. Common Stock
CFMS
| $3.19M | 1.92% |
+88,027
| New | +$3.69M |
2018 Q1
0 quarters
|
|
18
Omnicell
OMCL
$1.62B
| $3.05M | 1.83% |
+70,226
| New | +$3.23M |
2018 Q1
0 quarters
|
|
19
Philips
PHG
$24.4B
| $2.94M | 1.77% |
101,101
+11,742
| +13% | +$349K |
2016 Q1
8 quarters
|
|
20
PUT
DELISTED
Immunogen Inc
IMGN
| $2.89M | 1.74% |
+274,800
| New | +$2.71M |
2018 Q1
0 quarters
|
|
21
Viatris
VTRS
$20.3B
| $2.84M | 1.71% |
+69,000
| New | +$2.94M |
2018 Q1
0 quarters
|
|
|
CELG
22
DELISTED
Celgene Corp
CELG
| $2.78M | 1.67% |
+31,180
| New | +$2.99M |
2018 Q1
0 quarters
|
|
23
PUT
Johnson & Johnson
JNJ
$606B
| $2.56M | 1.54% |
+20,000
| New | +$2.7M |
2018 Q1
0 quarters
|
|
24
Lite Strategy Inc
LITS
$35.9M
| $1.94M | 1.16% |
46,728
+5,382
| +13% | +$234K |
2017 Q4
1 quarter
|
|
|
HRC
25
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $1.87M | 1.12% |
+21,449
| New | +$1.83M |
2018 Q1
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, Sio Capital Management held 63 positions worth $166M, down 6.1% from $177M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Sio Capital Management deployed $57M of net new capital in Q1 2018, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Sanofi: 408,621 shares worth $16.4M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 53% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Aetna Inc, an estimated $4.75M trimmed.
- Sio Capital Management's largest Q1 2018 buy was Sanofi: 408,621 shares worth $16.4M.
- Sio Capital Management added most to Gyre Therapeutics in Q1 2018, an estimated $23.6M increase.
- Sio Capital Management's biggest Q1 2018 reduction was Aetna Inc, cutting an estimated $4.75M.
- Sio Capital Management fully exited GSK in Q1 2018, selling an estimated $11.6M.
- Sio Capital Management's ten largest holdings make up 66% of its $166M portfolio in Q1 2018.
- Sio Capital Management opened 18 new positions and closed 32 in Q1 2018.
- Sio Capital Management's portfolio value fell 6.1% quarter-over-quarter to $166M.
Based on Sio Capital Management's 13F filing for Q1 2018, filed 15 May 2018.